Date: 2014-11-24
Type of information: Development agreement
Compound: compounds targeting a specific kinase involved in neurodegeneration
Company: MRC Technology (UK) Yabao Pharmaceuticals (China)
Therapeutic area: Neurodegenerative diseases
Type agreement: development commercialisation
Action mechanism:
Disease: Parkinson’s disease
Details: * On November 24, 2014, MRC Technology, a medical research charity, and Yabao Pharmaceutical, a leading pharmaceutical company in China, announced an exclusive license agreement to discover, develop and commercialise innovative compounds targeting a specific kinase involved in neurodegeneration, with the aim of developing novel therapeutics for the treatment of Parkinson’s disease. Under the terms of the agreement, Yabao receives exclusive rights to discover, develop and commercialise the therapeutics in China, Taiwan and Hong Kong whilst MRC Technology retains rights in all other markets.
Financial terms: Financial terms have not been disclosed.
Latest news:
